The FDA approved niraparib and abiraterone acetate (Akeega) in combination with prednisone for treating BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC), the agency announced on ...
Expanded indication for AKEEGA ® (niraparib and abiraterone acetate dual-action tablet) plus prednisone marks the first FDA-approved precision medicine combination treatment for patients with ...
Decision making is evidence based and must be shielded from lobbying The NHS draft recommendation against routine prostate ...
Leading scientists are advocating for annual prostate cancer screening for men with BRCA1 and BRCA2 gene mutations. Experts at the London-based Institute of Cancer Research (ICR) state that the ...
Cancer charity highlights apparent ‘postcode lottery’ of testing and diagnoses across different regions seen in study ...
Prostate cancer has overtaken breast cancer to become the most common form of the disease in the UK for the first time.
It’s a problem with not nearly enough attention. Prostate cancer hits men hard all over the world—it’s one of the biggest ...
In patients with BRCA2-mutated mCSPC, treatment with Akeega significantly reduced the risk of radiographic progression or death by 54%. The Food and Drug Administration (FDA) has approved Akeega ® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback